アレルギーと臨床免疫学の最新動向を、スペイン、バレンシアで開催される「EAACI Congress 2024」で網羅
March 19, 2024 07:42 ET
|
European Academy of Allergy and Clinical Immunology
http://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 スペイン、バレンシア発, March 19, 2024 (GLOBE NEWSWIRE) --...
Informieren Sie sich über die neuesten Entwicklungen auf dem Gebiet der Allergie und klinischen Immunologie auf dem EAACI-Kongress 2024 in Valencia, Spanien
March 19, 2024 07:42 ET
|
European Academy of Allergy and Clinical Immunology
http://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALENCIA, Spanien, March 19, 2024 (GLOBE NEWSWIRE) -- Die Europäische Akademie für Allergologie und...
Couvrez les derniers développements en matière d'allergie et d'immunologie clinique lors du Congrès 2024 de l'EAACI à Valence en Espagne
March 19, 2024 07:42 ET
|
European Academy of Allergy and Clinical Immunology
http://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALENCE, Espagne, 19 mars 2024 (GLOBE NEWSWIRE) -- L'European Academy of Allergy and Clinical Immunology...
Cover the Latest Developments in Allergy and Clinical Immunology at the EAACI Congress 2024 in Valencia, Spain
March 19, 2024 07:42 ET
|
European Academy of Allergy and Clinical Immunology
https://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALENCIA, Spain, March 19, 2024 (GLOBE NEWSWIRE) -- The European Academy of Allergy and Clinical...
Sema4 to Participate at Two Investor Conferences in June 2022
May 26, 2022 08:00 ET
|
Sema4
STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate...
Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2022 16:05 ET
|
Sema4
STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the...
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
May 02, 2022 07:45 ET
|
Sema4
Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx,...
Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
April 26, 2022 16:05 ET
|
Sema4
STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
Sema4 Achieves HITRUST CSF Certification
April 06, 2022 08:00 ET
|
Sema4
STAMFORD, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that its health intelligence platform,...
Sema4 Announces Nationwide Expansion of Disparity Study to Deliver Precision Oncology Care to Underserved Communities
March 16, 2022 08:00 ET
|
Sema4
- The REPRESENT Study Will Create One of the Most Diverse and Comprehensive Clinico-genomic Datasets to Uncover and Address Disparities in Cancer Care - Sema4’s Chief Medical Science Officer Will...